Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[How effective are PDE-5 inhibitors?].

K-P Jünemann1

  • 1Klinik für Urologie, Klinikum der Christian-Albrechts-Universität zu Kiel. kjuenemann@urology.uni-kiel.de

Der Urologe. Ausg. A
|April 26, 2003
PubMed
Summary

When comparing erectile dysfunction treatments, new phosphodiesterase-5 (PDE-5) inhibitors offer no proven advantage over Sildenafil. Current data suggests Sildenafil remains the gold standard due to high patient satisfaction and available counseling data.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgeon and surgical conference attendee views on live surgery events.

The British journal of surgery·2021
Same author

Der Urologe. Ausg. A·2021
Same author

[Quality of life in patients who suffered erectile dysfunction and underwent penile implant surgery in terms of sexual satisfaction of the patient and partner].

Der Urologe. Ausg. A·2020
Same author

[Epidemiology of penile cancer].

Der Urologe. Ausg. A·2018
Same author

[Robot-assisted Pylorus-Preserving Partial Pancreaticoduodenectomy (Kausch-Whipple Procedure)].

Zentralblatt fur Chirurgie·2016
Same author

[Salvage lymphadenectomy in patients with prostate cancer recurrence: A review].

Der Urologe. Ausg. A·2015

Area of Science:

  • Urology
  • Pharmacology
  • Sexual Medicine

Background:

  • Efficacy is a primary consideration for selecting erectile dysfunction (ED) therapies.
  • Phosphodiesterase-5 (PDE-5) inhibitors' efficacy relies on subjective patient-reported outcomes.
  • Quantifying ED treatment efficacy presents challenges due to patient variability.

Purpose of the Study:

  • To compare the efficacy of Sildenafil, Tadalafil, and Vardenafil for treating erectile dysfunction.
  • To evaluate whether newer PDE-5 inhibitors demonstrate superior efficacy compared to Sildenafil.
  • To assess the availability of patient counseling data for different ED medications.

Main Methods:

  • Analysis of existing clinical data comparing Sildenafil, Tadalafil, and Vardenafil.
  • Consideration of patient populations with varying ED severity and placebo response rates.
  • Examination of study exclusion criteria, particularly regarding prior Sildenafil treatment failure.

Main Results:

  • Newer PDE-5 inhibitors (Tadalafil, Vardenafil) show no significant efficacy advantage over Sildenafil when accounting for study limitations.
  • Patients who did not respond to Sildenafil were often excluded from trials of newer agents.
  • Sildenafil demonstrates a high degree of patient satisfaction and extensive counseling data.

Conclusions:

  • Based on current evidence, newer PDE-5 inhibitors do not surpass Sildenafil in efficacy for erectile dysfunction.
  • Sildenafil remains the established 'gold standard' for ED therapy, against which other treatments should be compared.
  • Comprehensive patient counseling data is currently most robust for Sildenafil, supporting its continued use.

Related Experiment Videos